Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.51 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.51 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.51 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.51 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.51 |
| ▸ | GJB2 | P29033 | 2/20 | 0.51 |
| ▸ | CDC25B | P30305 | 8/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776650 | 1.00 | PTPN1 (0.52) | PTPN1PTPN2PTPN11NT5ESSTR1 | |
| SCHEMBL9727044 | 0.94 | GJB2 (0.51) | PTPN1PTPN2PTPN11NT5ESSTR1 | |
| SCHEMBL9727043 | 0.94 | GJB2 (0.51) | PTPN1PTPN2PTPN11NT5ESSTR1 | |
| SCHEMBL4761024 | 0.91 | SSTR1 (0.55) | PTPN1PTPN2PTPN11NT5ESSTR1 | |
| SCHEMBL4761028 | 0.91 | SSTR1 (0.55) | PTPN1PTPN2PTPN11NT5ESSTR1 | |
| SCHEMBL9727220 | 0.91 | PTPN1 (0.47) | PTPN1PTPN2PTPN11NT5ESSTR1 | |
| SCHEMBL9727225 | 0.91 | PTPN1 (0.47) | PTPN1PTPN2PTPN11NT5ESSTR1 | |
| SCHEMBL2577647 | 0.91 | HTR1A (0.51) | PTPN1PTPN2PTPN11NT5ESSTR1 | |
| SCHEMBL13129825 | 0.91 | HTR1A (0.51) | PTPN1PTPN2PTPN11NT5ESSTR1 | |
| SCHEMBL21172782 | 0.91 | HTR1A (0.51) | PTPN1PTPN2PTPN11NT5ESSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943584-B2 | Medicinal composition containing diabetes remedy | SANKYO COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-1589023-B1 | OLIGOSACCHARIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7632930-B2 | Oligosaccharide derivative | SANKYO COMPANY LIMITED (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20080194495-A1 | Oligosaccharide Derivative | HONDA TAKESHI | 2008-08-14 | — | — | US | disclosed |
| US-20080039367-A1 | Medicinal Composition Containing Diabeted Remedy | SANKYO COMPANY, LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1792620-A1 | MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY | Sankyo Company, Limited (JP) | 2007-06-06 | — | — | EP | disclosed |
| EP-1589023-A1 | OLIGOSACCHARIDE DERIVATIVE | Sankyo Company, Limited (JP) | 2005-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039367-A1 | Medicinal Composition Containing Diabeted Remedy | DPP4, IAPP, AMY2A | PTPN1 175/4885PTPN2 343/4885PTPN11 160/4885 |
| US-20080194495-A1 | Oligosaccharide Derivative | MAN1B1, FUT6, MAN2A1 | PTPN1 1359/4885PTPN2 1866/4885PTPN11 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.